Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Sarcoma 1Genitourinary 1Breast 1

Conditions

Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tertiary Lymphoid Structures 1Sarcoma 1Pancreatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 6Nivolumab 3Gemcitabine 3Cisplatin 3Carboplatin 3brigimadlin 2Ramucirumab 2Fluorouracil 2Docetaxel 2Cetuximab 2tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1regorafenib 1pertuzumab 1milademetan 1larotrectinib 1futibatinib 1durvalumab 1cemiplimab 1adagrasib 1Trastuzumab 1TAS-116 1Ritonavir 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Omacor 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × brigimadlin × Thoracic × Clear all
NCT05512377 2026-05-14

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Boehringer Ingelheim

Phase 2 Terminated
99 enrolled
GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

NCT06084689 2025-09-02

EMPIRE

Institut Bergonié

Phase 2 Withdrawn
BreastGastrointestinalSarcomaThoracic

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡